Infectious disease and transplantation: Messages for the generalist

Cleveland Clinic Journal of Medicine

Volumn 65, Issue 6, 1998, Pages 305-314

  Avery, Robin K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN; AZITHROMYCIN; CHICKENPOX VACCINE; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; ERYTHROMYCIN; FLUCONAZOLE; FOSCARNET; HEPATITIS B VACCINE; ITRACONAZOLE; KETOCONAZOLE; MEASLES MUMPS RUBELLA VACCINE; PENTAMIDINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; QUINOLONE DERIVATIVE;

BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION PREVENTION; INFECTION RISK; LONG TERM CARE; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; REVIEW; VACCINATION;

EID: 0031834667     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.65.6.305     Document Type: Review

References (12)

1. Rubin RH. Infection in the organ transplant recipient. In Rubin RH, Young LS, editors. Clinical Approach to Infection in the Compromised Host. 3rd ed. New York: Plenum Medical Book Company, 1994:629-705.
2. Hibberd PL, Rubin RH. Approach to immunization in the immunosuppressed host. Infect Dis Clin North Am 1990; 4:123-142.
3. Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics 1992; 90:215-220.
4. Avery RK, Barnes D, Teran JC, et al. Listeria monocytogenes tricuspid valve endocarditis with septic pulmonary emboli in a liver transplant recipient. Personal communication, 1998.
5. Falagas M, Snydman DR. Evaluation of a liquid and virally inactivated formulation of cytomegalovirus immune globulin combined with ganciclovir in liver transplant recipients at risk for primary infection. Personal communication, 1998.
6. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317:1049-1054.
7. Basgoz N, Hibberd PL, Tolkoff-Rubin NE, et al. Possible role of cytomegalovirus disease in the pathogenesis of post-transplant lymphoproliferative disorder. Abstract P-150, 12th Annual Meeting, American Society of Transplant Physicians, Houston, 1993.
8. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61:1279-1289.
9. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123:18-26.
10. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118:179-184.
11. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118:173-178.
12. Avery R, Longworth D, Pohlman B, et al. Prophylaxis of invasive aspergillosis with itraconazole in allogeneic bone marrow transplant recipients. Abstract #531, 16th Annual Meeting, American Society of Transplant Physicians, Chicago, 1997.